Company Profile
Getein Biotech, Inc. (Chinese: 基蛋生物科技股份有限公司) is a China-based manufacturer of in-vitro diagnostic (IVD) reagents and analytical instruments, headquartered in Nanjing, Jiangsu. Founded on 8 March 2002 by Dr. Su Enben, a former cardiologist at Jiangsu Provincial People's Hospital, the company was listed on the Shanghai Stock Exchange (603387) in July 2017. Getein operates as a leading domestic IVD provider with integrated R＆D, manufacturing, and sales capabilities.
Core Products ＆ Technologies
Point-of-Care Testing (POCT)
• Cardiac Markers: Rapid quantitative assays for cTnI, NT-proBNP, D-Dimer, and CK-MB for emergency and bedside cardiac diagnosis
• Inflammatory Markers: CRP, PCT, and SAA rapid tests for infection and sepsis screening
• Renal Function ＆ Metabolic Panels: Rapid tests for kidney function, blood glucose, and glycated hemoglobin
Chemiluminescence Immunoassay (CLIA)
• MAGICL 6000: Compact fully-automatic chemiluminescence analyzer with whole-blood detection capability; designed for emergency departments and clinical wards
• MAGICL 6000i: High-throughput chemiluminescence analyzer for clinical laboratories and primary care markets
• Assay Menu: 105+ tests covering cardiac markers, inflammation, thyroid function, tumor markers, fertility, and diabetes; cumulative installations reached approximately 2,800 units by end of 2025
Automated Biochemistry ＆ Immunoassay Lines
• Metis 6000: Fully automated biochemistry-immunoassay pipeline integrating MAGICL 6200 immunology module (400 T/H) and CM-1000 biochemistry module (1,000 T/H); smallest footprint in its class; 150+ installations by Q1 2026, with over 70% deployed in secondary and lower-tier hospitals
• Metis 7000: Next-generation high-capacity pipeline integrating sample pre-processing, intelligent storage, and combined biochemistry-immunoassay detection; 23 major categories with nearly 400 test items; targeting tertiary hospitals
Molecular Diagnostics ＆ Other Platforms
• GN 7000: Fully automated nucleic acid amplification analyzer featuring integrated extraction, amplification, and detection; 40+ installations since December 2024 launch
• Getein 1600: Small-volume, high-speed chemiluminescence analyzer; nearly 150 units installed in Q1 2026
• Coagulation Testing: Thrombosis and hemostasis diagnostic reagents and instruments
• Raw Material Self-Supply: Antibody self-production rate exceeding 90%, covering cardiac, inflammatory, coagulation, tumor, metabolic, and infectious disease panels
Market Position ＆ Certifications
Getein holds a leading position in China's domestic POCT and chemiluminescence market, competing with Roche Diagnostics, Abbott, Mindray, Snibe (New Industries Biomedical Engineering), and Autobio Diagnostics. Key strengths include:
• 23+ years of IVD innovation heritage
• Full-chain integration: Self-developed reagents, instruments, and key raw materials (antibodies, antigens) with over 90% self-sufficiency
• Regulatory compliance: NMPA registered products, CE marked exports, and ISO 13485 certified manufacturing; 2,500+ overseas registrations covering 66 countries and regions
• Dual-engine growth: POCT legacy business complemented by rapidly expanding chemiluminescence and pipeline product lines (chemiluminescence revenue grew 20.58% in 2025)
• Cost advantage: Vertical integration and optimized supply chain maintaining gross margin near 70% despite pricing pressures
Corporate Timeline
2002 — Founded in Nanjing by Dr. Su Enben as Nanjing Getein Biotech
2017 — Listed on Shanghai Stock Exchange Main Board (603387)
2024 — Annual revenue reached RMB 1.165 billion; Metis 6000 pipeline launched; GN 7000 molecular platform introduced
2025 — Annual revenue of RMB 1.052 billion with net profit of RMB 221 million; overseas routine product revenue grew 28.87% year-over-year; small chemiluminescence (MAGICL 6000/6000i) installed 1,100+ units; R＆D investment reached RMB 167 million
2026 — Q1 revenue of RMB 267.5 million (up 9.57% YoY) with overseas self-produced product revenue up 48.55%; Getein 1600 installed nearly 150 units, MAGICL 6000/6000i installed 170+ units, Metis 6000 installed 10+ lines in Q1; reached comprehensive settlement with Wuhan Jingchuan Diagnostics on April 22, divesting all equity; board secretary transitioned from Liu Cong to Tang Xu
Target Markets ＆ Applications
• Emergency ＆ Critical Care: Rapid cardiac and inflammatory marker testing in emergency departments and ICUs
• Clinical Laboratory Automation: High-throughput chemiluminescence and biochemistry-immunoassay integration for hospital labs
• Primary Care ＆ Rural Health: Compact POCT and small chemiluminescence systems for county-level hospitals and community clinics
• Molecular Infectious Disease Testing: Respiratory, gastrointestinal, and reproductive health panels via GN 7000 platform
• Global Emerging Markets: Export-focused IVD solutions for Asia, Europe, Africa, and Latin America
Contact Information
Global Headquarters
Address: No. 9 Bofu Road, Yanjiang Industrial Development Zone, Luhe District, Nanjing, Jiangsu 211505, China
Phone: +86 25 6856 8577
Email: IR@gtein.cn
Website: www.getein.com
